We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 61-80 of 4,064 results
  1. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies

    Clostridioides difficile  is one of the most important causes of healthcare-associated diarrhea. The high incidence and recurrence rates of  C. difficile ...

    Parul Berry, Sahil Khanna in BioDrugs
    Article 26 July 2023
  2. Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers

    Purpose

    A population pharmacokinetic model of fosfomycin was developed in healthy volunteers after intravenous administration, and different dosing...

    Angela Elma Edwina, Birgit C. P. Koch, ... Sebastiaan D. T. Sassen in European Journal of Clinical Pharmacology
    Article Open access 15 April 2023
  3. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature

    Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug...

    Barthelemy Lafon-Desmurs, Benoit Gachet, ... Eric Senneville in European Journal of Clinical Microbiology & Infectious Diseases
    Article 16 May 2024
  4. New Promising Antimicrobials in Development and Novel Approaches for Treatment of Infections

    Despite the approval of several new antibiotics in the last several years, there is still an unmet need for treating multidrug-resistant bacteria,...
    Chapter 2023
  5. Linezolid pharmacokinetics: a systematic review for the best clinical practice

    Objectives

    To summarize the pharmacokinetics of linezolid to optimize the dosing regimen in special populations.

    Methods

    A literature search was...

    Shima Heidari, Hossein Khalili in European Journal of Clinical Pharmacology
    Article 24 December 2022
  6. A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

    Purpose

    The purpose of this phase 3 study was to evaluate the efficacy, pharmacokinetics (PK), and safety of Immune Globulin Subcutaneous (Human), 20%...

    Manuel Santamaria, Olaf Neth, ... Jiang Lin in Journal of Clinical Immunology
    Article Open access 01 January 2022
  7. Resistance in Tuberculosis: Molecular Mechanisms and Modulation

    Since the time of years following World War II, tuberculosis (TB) has become a treatable disease due to the discoveryDiscoverydrug of...
    Himanshu Verma, Shalki Choudhary, Om Silakari in Tuberculosis
    Chapter 2023
  8. Efficacy of 3-day low dose quinine plus clindamycin versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children (CLINDAQUINE): an open-label randomized trial

    Background

    The World Health Organization recommends quinine plus clindamycin as first-line treatment of malaria in the first trimester of pregnancy...

    Charles O. Obonyo, Elizabeth A. Juma, ... Bernhards R. Ogutu in Malaria Journal
    Article Open access 02 February 2022
  9. Association of antimicrobial perioperative prophylaxis with cefuroxime plus metronidazole or amoxicillin/clavulanic acid and surgical site infections in colorectal surgery

    Objective

    To compare intravenous (IV) amoxicillin/clavulanic acid (A/CA) to IV cefuroxime plus metronidazole (C + M) for preventing surgical site...

    Elisavet Stavropoulou, Andrew Atkinson, ... Nicolas Troillet in Antimicrobial Resistance & Infection Control
    Article Open access 19 September 2023
  10. The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis

    Background

    The gut microbiota can affect neurologic disease by sha** microglia, the primary immune cell in the central nervous system (CNS). While...

    Laura M. Cox, Narghes Calcagno, ... Howard L. Weiner in Microbiome
    Article Open access 11 March 2022
  11. Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice

    Schistosomiasis threatens hundreds of millions of people worldwide. The larval stage of Schistosoma mansoni migrates through the lung and adult worms...

    Adam S. Hassan, Sébastien Houle, ... Momar Ndao in npj Vaccines
    Article Open access 27 February 2023
  12. Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report

    Background

    Combination therapy with tazobactam/ceftolozane (TAZ/CTLZ) and high-dose aminoglycosides has been reported to be efficacious in extensively...

    Yuta Ibe, Ryuichiro Kakizaki, ... Masahide Fukudo in Journal of Pharmaceutical Health Care and Sciences
    Article Open access 08 August 2023
  13. Current state of neuroprotective therapy using antibiotics in human traumatic brain injury and animal models

    TBI is a leading cause of death and disability in young people and older adults worldwide. There is no gold standard treatment for TBI besides...

    Katharina Ritter, Pawit Somnuke, ... Michael K.E. Schäfer in BMC Neuroscience
    Article Open access 29 February 2024
  14. Formulation, pharmacokinetics, and antibacterial activity of florfenicol-loaded niosome

    The growing interest in employing nano-sized pharmaceutical formulations in veterinary medicine has prompted the exploration of the novel...

    Shimaa G. Abonashey, Hatem A. F. M. Hassan, ... Hossny A. El-Banna in Drug Delivery and Translational Research
    Article Open access 13 November 2023
  15. Photodynamic Inactivation of Mycobacterium tuberculosis Using Alluminium Phthalocyanine

    In a series of in vitro experiments, the optimum regimes of laser treatment were determined for effective photodynamic inactivation of Mycobacterium...

    S. D. Nikonov, D. A. Bredikhin, ... Ya.Sh. Schwartz in Bulletin of Experimental Biology and Medicine
    Article 01 July 2023
  16. Potential of Curcumin Nanoparticles in Tuberculosis Management

    Tuberculosis (TB), the deadliest infectious-disease caused by Mycobacterium tuberculosis (M.tb) created a global-threat to the entire human race...
    Bhabani Shankar Das, Ashirbad Sarangi, Debapriya Bhattacharya in Bio-Nano Interface
    Chapter 2022
  17. Doxycycline for transgene control disrupts gut microbiome diversity without compromising acute neuroinflammatory response

    The tetracycline transactivator (tTA) system provides controllable transgene expression through oral administration of the broad-spectrum antibiotic...

    Emily J. Koller, Caleb A. Wood, ... Joanna L. Jankowsky in Journal of Neuroinflammation
    Article Open access 04 January 2024
  18. Nano vs Resistant Tuberculosis: Taking the Lung Route

    Tuberculosis (TB) is among the top 10 infectious diseases worldwide. It is categorized among the leading killer diseases that are the reason for the...

    Deepika Sharma, Pooja, ... Manisha Pandey in AAPS PharmSciTech
    Article 04 December 2023
  19. A systematic review of the drug-drug interaction between Statins and Quinolones

    Background

    Statins are widely used in cardiovascular disease (CVD) as a common lipid-lowering drug, while quinolones are widely used for the treatment...

    Jifang Zhou, Lixia Yu, Huimin Xu in BMC Pharmacology and Toxicology
    Article Open access 10 July 2024
  20. The Pharmacokinetic and Pharmacodynamic Properties of Antitubercular Medications

    PharmacokineticsPharmacokinetics and pharmacodynamicsPharmacodynamics operate in a partnership that can be used to maximize a drug’s potential for...
    Ashlan J. Kunz Coyne, Anthony M. Casapao, Eric F. Egelund in Tuberculosis
    Chapter 2023
Did you find what you were looking for? Share feedback.